Navigation Links
Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer
Date:12/14/2010

may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements include statements about future activities related to the complete response letter regarding the company's new drug application for Linjeta™; the company's response to the complete response letter; the importance of the complete response letter; and the company's focus, goals, strategy, research and development programs, and ability to develop and commercialize product candidates.  Forward-looking statements represent our management's judgment regarding future events.  All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements.  The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to respond to the complete
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Reports Fourth Quarter and Fiscal Year 2010 Financial Results
2. Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
3. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
4. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
5. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta™
6. Biodel to Present at Upcoming Conferences
7. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
8. Biodel Appoints Arthur Urciuoli to its Board of Directors
9. Biodel to Raise $9.4 Million Through Registered Direct Offering
10. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
11. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... the Morgan Stanley Healthcare conference on Tuesday, September ... Huennekens , president and chief executive officer, will ...
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... corporate and clinical activities at the company ... ongoing clinical trials and future clinical development ... Executive Officer Robert Hershberg , M.D., ...
(Date:9/2/2014)... Sept. 2, 2014  VentiRx Pharmaceuticals, Inc., ... the development and commercialization of novel Toll-like ... the U.S. Food and Drug Administration (FDA) ... investigation of motolimod (VTX-2337) when administered in ... the treatment of women with ovarian cancer ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... May 20, 2011 Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) ... intermediates, and contract research and manufacturing services to customers ... the 2011 fiscal year (FY) ended March 31, 2011. ... in fiscal year 2011, Neuland delivered on our commitment ...
... Winner Medical Group Inc. (Nasdaq: WWIN ; ... medical dressings, medical disposables and non-woven fabric made from ... that its PurCotton Industrial Wipes was nominated one of ... Award™. The Company will compete with the ...
Cached Medicine Technology:Neuland Labs Reports Financial Results for Fiscal Year 2011 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 3Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 4
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
(Date:9/2/2014)... Moroccan Eco-Biologics’ new one-of-a-kind Vitality Hair Recovery ... the foundation of all natural Moroccan plant extracts to ... There is nothing similar to Vitality Hair Recovery cream ... is a commonly encountered problem for men and women ... been limited to existing medications offering mediocre results, considerable ...
(Date:9/2/2014)... September 02, 2014 Humility of Mary Health ... 18 at St. Elizabeth Health Center, 1044 Belmont Ave. , ... about more than 200 common health problems as well as ... and injury, and advice on when to seek medical attention. ... noon in the Youngstown Room; the evening session runs from ...
(Date:9/2/2014)... is pleased to announce that the following papers ... the ESC Congress 2014, taking place in Barcelona, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus ... (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Windecker et ... strut thickness, surface polymer, and drug release have ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 Researchers in ... woman who developed mesothelioma after being exposed to asbestos-contaminated work ... has all the details of the report in a new ... Doctors at the ESI Model Hospital say their patient was ... and breathlessness. Further investigation found that she had come in ...
Breaking Medicine News(10 mins):Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2
... , NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... develops novel therapeutic proteins that disrupt the advance of ... in the process of acquiring three promising new drug ... in royalty fees in the mid to long term. ...
... , , , ... to those who are here illegally," President Obama said in a carefully ... last night. The problem, notes the Federation for American Immigration Reform (FAIR), ... Health Care Act of 2009, clearly would benefit illegal aliens. , ...
... , , SAN FRANCISCO, ... professional association in U.S. history took a major step forward ... Nurses Association/National Nurses Organization in San Francisco voted unanimously to ... National Nurses United, unifying the 86,000-member CNA/NNOC with the ...
... (GSA) invites all journalists to attend its 62nd Annual ... the field of aging from November 18 to 22 ... An estimated 3,500 professionals are expected to attend the ... Atlanta Marriott Marquis . The theme for 2009 is "Creative ...
... The University of Miami School of Nursing and Health Studies ... Foundation in the amount of $30,000 to support six students ... program. "Family nurse practitioners have a promising future" said Nilda ... Studies. "The Dr. John T. Macdonald Foundation grant will help ...
... , , LAKE FOREST, Ill., ... leading global specialty pharmaceutical and medication delivery company, today announced that ... on Thursday, Sept. 17, 2009. The company,s senior leadership team and ... , A streaming audio webcast of the event, ...
Cached Medicine News:Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 2Health News:GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees 3Health News:President Obama Misleads Public on Health Care for Illegal Aliens; Illegal Aliens Would Benefit Under H.R. 3200 2Health News:California Nurses/NNOC, Nation's Largest Nurses' Organization, Unanimously Endorses Joining RN Super Union 2Health News:An invitation to the nation's premier aging conference 2Health News:UM receives grant to support graduate students in the family nurse practitioner program 2Health News:Hospira to Host 2009 Investor Day 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: